Xiang Hu, Lin Chen, Yian Du, Biao Fan, Zhaode Bu, Xin Wang, Yingjiang Ye, Zhongtao Zhang, Gang Xiao, Fei Li, Qingsi He, Guoli Li, Xian Shen, Bin Xiong, Liming Zhu, Jiwei Liu, Lian Liu, Tao Wu, Jing Zhou, Jun Zhang, Gang Zhao, Xulin Wang, Pin Liang, Xinxin Wang, Yan Zhang, Xiaojiang Wu, Ji Zhang, Xin Ji, Xianglong Zong, Tao Fu, Ziyu Jia, Jiafu Ji

1Department of Gastrointestinal Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;2Department of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;3Department of Abdominal Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China;4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China;5Department of General Surgery, Peking University First Hospital, Beijing 100034, China;6Department of Gastrointestinal Surgery, Peking University People’s Hospital, Beijing 100044, China;7Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;8Department of General Surgery, Beijing Hospital, Beijing 100730, China;9Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China;10Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China;11Department of General Surgery, Nanjing General Hospital, Nanjing 210002, China;12Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;13Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;14Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China;15Department of Medical Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;16Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan 250012, China

*These authors contributed equally to this work.

Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial

Xiang Hu1*, Lin Chen2*, Yian Du3*, Biao Fan4*, Zhaode Bu4*, Xin Wang5, Yingjiang Ye6, Zhongtao Zhang7, Gang Xiao8, Fei Li9, Qingsi He10, Guoli Li11, Xian Shen12, Bin Xiong13, Liming Zhu14, Jiwei Liu15, Lian Liu16, Tao Wu5, Jing Zhou6, Jun Zhang7, Gang Zhao8, Xulin Wang11, Pin Liang1, Xinxin Wang2, Yan Zhang9, Xiaojiang Wu4, Ji Zhang4, Xin Ji4, Xianglong Zong4, Tao Fu4, Ziyu Jia4, Jiafu Ji4

1Department of Gastrointestinal Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;2Department of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;3Department of Abdominal Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China;4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China;5Department of General Surgery, Peking University First Hospital, Beijing 100034, China;6Department of Gastrointestinal Surgery, Peking University People’s Hospital, Beijing 100044, China;7Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;8Department of General Surgery, Beijing Hospital, Beijing 100730, China;9Department of General Surgery, Xuanwu Hospital Capital Medical University, Beijing 100053, China;10Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China;11Department of General Surgery, Nanjing General Hospital, Nanjing 210002, China;12Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China;13Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;14Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China;15Department of Medical Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;16Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan 250012, China

*These authors contributed equally to this work.

Background:The ACTS-GC study had shown postoperative adjuvant therapy with S-1 improved survival of patients with locally advanced gastric cancer. Addition of oxaliplatin to S-1 is considered to be acceptable as one of the treatment options for gastric cancer patients after radical gastrectomy with D2 lymph node excision.

Methods:We have commenced a randomized phase III trial in December 2016 to evaluate S-1 plus oxaliplatin compared with S-1 alone in the adjuvant setting for locally advanced gastric cancer. A total of 564 patients will be accrued from 13 Chinese institutions in two years. The primary endpoint is 3-year relapse-free survival. The secondary endpoints are 5-year overall survival, proportion of patients who complete the postoperative chemotherapy and incidence of adverse events.

Ethic and dissemination:The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient’s follow-up will be ended until December, 2023.

Trial registration:ClinicalTrials.gov, identifier: NCT02867839. Registered on August 4, 2016.

Locally advanced gastric cancer; S-1 plus oxaliplatin; randomized phase III trial

View this article at:https://doi.org/10.21147/j.issn.1000-9604.2017.02.07

Background and rationale

Gastric cancer is the third most common cause of cancerrelated death worldwide (1). D2 gastrectomy is the standard of care in Asia (2,3). Various regimens for adjuvant chemotherapy have been recommended for the resectable gastric cancer to prevent postoperative recurrence (4-6). Two large randomized controlled trials, ACTS-GC and CLASSIC, have investigated the efficacy of adjuvant chemotherapy after D2 gastrectomyvs. D2 gastrectomy alone for patients with resectable gastric cancer. The ACTS-GC trial reported patients with stage II or IIIA gastric cancer who received S-1 after curative gastrectomy had better outcomes compared with patients who received surgery only (7). The 5-year overall survival (OS) rate was 71.7% in the S-1 group compared with 61.1% in the surgery only group. In the CLASSIC trial, the survival benefit was consistent with that in ACTS-GC (8). The 5-year OS rate was improved in the adjuvant capecitabine plus oxaliplatin group (78%vs. 69% in the surgery-only group). The benefits of fluoropyrimidinebased chemotherapy with one agent or two agents in stage II and IIIA gastric cancer were both considerable.

A meta-analysis suggests that treatment with several drugs could be more effective than treatment with using fewer drugs (9), but this finding has not been confirmed in the adjuvant setting (10). None of the sequential S-1-paclitaxel, sequential tegafur and uracil (UFT)-paclitaxel resulted in a superior outcome when compared with singleagent, adjuvant S-1 in the trial SAMIT (11). Nevertheless, no clinical trial evaluated the efficacy of adjuvant chemotherapy with S-1 plus oxaliplatin when compared to adjuvant S-1 alone. Because of high incidence of locally advanced gastric cancer in China, increasing number of older patients with comorbidities, conflicts between costly treatment strategy and limited medical resources, an effective, economical and feasible regimen for adjuvant chemotherapy is crucial there. In the current trial, we hypothesize that efficacy of adjuvant chemotherapy with S-1 in resectable gastric cancer is not inferior to that of S-1 plus oxaliplatin. Patients with stage II and IIIA gastric cancer are eligible. Postoperative chemotherapy with S-1 will be explored in a randomized comparison with S-1 plus oxaliplatin, one of the standard treatment options.

Digest of study protocol

Objectives

The aim of this trial is to evaluate the efficacy of S-1 alone compared with S-1 plus oxaliplatin for adjuvant treatment in locally advanced gastric cancer after D2 gastrectomy.

Study setting

This trial is a multi-institutional, prospective, open-label, randomized phase III trial.

Endpoints

The primary endpoint is the 3-year relapse-free survival (RFS) of all randomized patients. RFS is counted from the date of registration to the earliest date of tumor recurrence, and it is censored at the latest day when the patient is confirmed to be alive without any evidence of recurrence. The diagnosis of tumor relapse should be based on objective evidence of imaging test [computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT), B-ultrasound], endoscopy and/or histology. Elevated serum tumor marker cannot be used as direct evidence of tumor relapse. The secondary endpoints are 5-year OS, proportion of patients who complete the protocol treatment, and incidence of adverse events.

Eligibility criteria

Prior to enrollment in this trial, the patients must meet all the criteria below: 1) pathologically proven stage II or IIIA gastric adenocarcinoma. (The 8th edition of AJCC TNM classification); 2) no hepatic, peritoneal or distant metastasis; 3) negative peritoneal cytology; 4) R0 distal gastrectomy with radical D2 lymph node excision; 5) aged 18–70 years old; 6) performance status of either 0 or 1 on Eastern Cooperative Oncology Group (ECOG) criteria; 7) no previous chemotherapy or radiotherapy; 8) adequate major organ function as evidenced by the following laboratory findings: WBC >4.0×109/L, PLT >100×109/L, ALT and AST ≤2.5 times the upper limit of normal, and total bilirubin ≤1.5 times the upper limit of normal; 9) no unstable cardiac dysfunction and other organ diseases; 10) able to start chemotherapy 4–6 weeks after surgery; 11) not enrolled in other trials; and 12) written informed consent.

Exclusion criteria

Prior to enrollment in this trial, the patients must not meet any of the criteria below: 1) pregnant, possibly pregnant or lactating; 2) underwent prior treatment such as chemotherapy and radiotherapy; 3) history of serious drug hypersensitivity; 4) infectious disease requiring systemic therapy; 5) serious concomitant disease; or 6) determined by the investigator to be unsuitable for other reasons.

Randomization and allocation concealment

After confirming fulfillment of the eligibility criteria, registration is made by a web-based system to the Data Center (https://crabyter.sinyoo.net/). Patients will be randomized to either arm A [adjuvant chemotherapy with S-1 plus oxaliplatin (SOX)] or arm B (adjuvant chemotherapy with S-1 only). The minimization method will be used for the randomization of patients, thereby balancing the arms of the study according to gender, tumor depth and the institution. We hypothesize that both 3-year RFS and 5-year OS of arm B are not inferior to those of arm A. If no significant difference in patient survival of the two arms, the regimen with S-1 will be concluded as the standard treatment for II and IIIA stage gastric cancer after radical surgery.

Treatment methods

Postoperative chemotherapy

After the R0 resection, adjuvant chemotherapy will be initiated within 4–6 weeks from surgery (Figure 1). Patients in the arm A will receive 8 courses of SOX including an infusion of oxaliplatin (100 mg/m2d 1) and take S-1 (40–60 mg bid, d 1–14) every 3 weeks. Patients in the arm B will receive 16 courses of S-1 oral administration (40–60 mg bid, d 1–14) every 3 weeks. If the adjuvant treatment is not initiated within 6 weeks after surgery for any reason, the protocol treatment is terminated. The protocol treatment is terminated and any treatment is allowed when tumor relapse.

Adverse events and safety monitoring plan

An independent data and safety monitoring board (DSMB) will be formed to monitor data and safety. Incidence of adverse events will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Severe adverse events resulting from the trial will be informed to the principle investigator and be treated until symptoms typically disappear or become less intense.

Figure 1The study flow chart.

Follow-up

Patients will be followed-up every 3 months for the following 2 years after surgery, and subsequently every half year for the next 3 years. Follow-up evaluations will include a physical examination, blood tests such as complete blood cell count, measurements of liver and renal function, gastrointestinal tumor markers, abdominal and pelvic enhanced CT scan, chest plain CT scan and hepatic enhanced MRI scan when atypical focal liver lesion occurs. Upper gastrointestinal endoscopy will be conducted per year.

Sample size calculation and statistical analysis

According to the statistical tools on SWOG center (http://www.swogstat.org/), the required sample size will be 564 patients (282 patients per arm), with a one-sided alpha level of 5% and a power of 80%. Analyses of efficacy of chemotherapy were based on both intent-to-treat (ITT) set and the per-protocol (PP) set. Data related to patient characteristics will be compared between two arms by using the Chi-square test. Cumulative survival will be estimated with the Kaplan-Meier method, and comparisons betweenthe arms will be done with a Log-rank test. A multivariate analysis of the Cox proportional hazards regression model (backward, stepwise) will be created to assess the influence of each variable on survival. Significance will be set at P<0.05. All statistical analyses were carried out using the IBM SPSS Statistics (Version 19.0; IBM Corp., New York, USA).

Clinical trials registry

This trial has been registered in the ClinicalTrials.gov as NCT02867839 (https://clinicaltrials.gov/).

Participating institutions

Peking University Cancer Hospital & Institute, the First Affiliated Hospital of Dalian Medical University, Chinese People’s Liberation Army General Hospital, Zhejiang Cancer Hospital, Peking University First Hospital, Peking University People’s Hospital, Beijing Hospital, Beijing Friendship Hospital of Capital Medical University, Xuanwu Hospital of Capital Medical University, Qilu Hospital of Shandong University, the First Affiliated Hospital of Wenzhou Medical University, Nanjing General Hospital, and Zhongnan Hospital of Wuhan University.

Trial status

The trial has been approved by the institutional review board of each participating institution and it was activated on December, 2016. The enrollment will be finished in December, 2018. Patient’s follow-up will be ended until December, 2023.

Acknowledgements

This study is supported by the National Science Foundation of China (No. 81374016 and 81402308), Beijing Municipal Science & Technology Commission (No. D141100000414002).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

1.Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

2.Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.

3.Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidencebased approach. J Gastric Cancer 2014;14:87-104.

4.Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-76.

5.Shitara K, Chin K, Yoshikawa T, et al. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. Gastric Cancer 2017;20:175-81.

6.Takahari D, Hamaguchi T, Yoshimura K, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011;67:1423-8.

7.Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29:4387-93.

8.Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96.

9.Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.

10.GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-37.

11.Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014;15:886-93.

Cite this article as:Hu X, Chen L, Du Y, Fan B, Bu Z, Wang X, Ye Y, Zhang Z, Xiao G, Li F, He Q, Li G, Shen X, Xiong B, Zhu L, Liu J, Liu L, Wu T, Zhou J, Zhang J, Zhao G, Wang X, Liang P, Wang X, Zhang Y, Wu X, Zhang J, Ji X, Zong X, Fu T, Jia Z, Ji J. Postoperative chemotherapy with S-1 plus oxaliplatin versus S-1 alone in locally advanced gastric cancer (RESCUE-GC study): a protocol for a phase III randomized controlled trial. Chin J Cancer Res 2017;29(2):144-148. doi: 10.21147/j.issn.1000-9604.2017.02.07

10.21147/j.issn.1000-9604.2017.02.07

Jiafu Ji, MD, PhD. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China. Email: jijiafu@hsc.pku.edu.cn.

Submitted Mar 10, 2017. Accepted for publication Apr 18, 2017.